FT500-101: FT500 as Monotherapy and in Combination with Immune Checkpoint Inhibitors in Subjects with AdvancedSolid Tumors

Project: Research project

Description

FT500-101: FT500 as Monotherapy and in Combination with Immune Checkpoint Inhibitors in Subjects with Advanced Solid Tumors
StatusActive
Effective start/end date10/1/1810/30/22

Funding

  • Fate Therapeutics, Inc.

Fingerprint

Neoplasms